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Structured summary: 
Background:  Research showing an association between proton pump inhibitors (PPIs) and Clostridium 
difficile infections has largely been undertaken in Europe and North America.  Clostridium difficile strains 
vary by region and may influence risk estimates across regions. 
Aim: To determine the association between incident proton pump inhibitor (PPI) use and Clostridium 
difficile infections across multiple countries 
Method:  National data covering the total population in Australia and Korea, the Canadian population 
over 65 years and a 3 million person random sample data set from Taiwan were assessed, as were data 
from a worker insurance population and a hospital inpatient/ outpatient population in Japan. Sequence 
symmetry analysis was used to assess the association with oral vancomycin dispensing as the outcome 
of interest. 
Results: 54,957 patients were included. Positive associations were observed in Australia; adjusted 
sequence ratio (ASR) 2.48 (95% CI 1.90, 3.12), Korea ASR 2.15 (95%CI 2.11, 2.19), Canada ASR 1.45 (95% 
CI 1.16, 1.79), Japan hospital dataset ASR 3.21 (95%CI 2.12, 4.55) and Japan worker insurance dataset 
ASR 5.40 (95% CI 2.73, 8.75).  The pooled result was ASR 2.40 (95%CI 1.88, 3.05) and 3.16 (95%CI 1.95, 
5.10) when limited to Asian countries. Results did not vary by individual PPI. The temporal analysis 
showed effects within the first two weeks of PPI initiation. 
Conclusion: When analysis was limited to the Asian countries, pooled risk estimates were higher than 
those which had been observed in European and North American populations. Research to identify 
reasons underpinning any risk difference in the Asian region is required.  
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Introduction 
There is a significant body of research showing an association between use of proton pump inhibitors 
and Clostridium difficile infections,1-5 however, limited research has been undertaken in Asia-Pacific 
populations.  A 2012 meta-analysis assessing the association between Clostridium difficile infections and 
proton pump inhibitor use included 51 studies and reported a pooled odds ratio of 1.65 (95% CI 1.47, 
1.85), however, only 3 observations were from the Asia region.1  When analysis was limited to the Asian 
observations, and the pooled result was higher at OR 3.26, (95%CI 1.91 -5.58.).1 
The prevalence of different strains of Clostridium difficile varies substantially by region. Ribotyping has 
shown that the most frequent ribotypes in Australia are 014 and 002,6 in China it is 017, 046, and 012; in  
Japan 018, 014, 002, 001,  Korea 018, 017, Taiwan 017, and Hong Kong it is 002.7  This compares with 
Europe where the ribotypes are 027, 014,001/072, and 078.8  This may have implications for the risk of 
clostridium difficile from proton pump inhibitors. In some clostridium difficile ribotypes the level of 
expression of toxin genes and their regulators was greater at higher pH levels and elevated even further 
in the presence of PPIs.9 For Ribotype 001, PPI exposure  was associated with a 120-fold higher 
expression of tcdA at higher pH levels, while for ribotypes 027 and 028, more than 50 fold increases 
were observed at higher pH levels.  For tcdB and cdtB expression the relationship was less clear.9    
Whether the differing prevalence of different strains of Clostridium difficile and the potential for PPIs to 
affect toxin gene expression differently according to strain means that differences in risk of PPI induced 
Clostridium difficile can be observed across countries is unclear.  
There has been only limited study of the association between proton pump inhibitors and risk of 
Clostridium difficile infection in the Asia Pacific region, with the majority of studies undertaken to date 
being from North America or Europe (48 of 51).1 No multi-country studies have been undertaken to 
date. Further many studies have been single centre sites (40 of 51), have been undertaken in the 
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hospital setting (37 of 51, 6 involved both hospital and community and 8 involved community only) and 
have been case-control studies (37 of 51).1  The majority of studies assessed any proton pump inhibitor 
exposure with limited analysis of the effect of incident use.  
To further add to the evidence base and address some of the limitations of prior research we undertook 
a multi-country study, which included 4 countries (6 databases) from the Asia Pacific region. We used a 
self-controlled method.  We had national data for four of the countries involved, thus providing the 
largest study sample to date to assess the association between proton pump inhibitor use and 
Clostridium difficile infection. 
Methods 
 
Data sources 
This multi country study was initiated by Health Canada, with participation from the member groups of 
the Asian PharmacoEpidemiology Network (AsPEN).10 AsPEN provides a mechanism to support the 
conduct of cross-country pharmacoepidemiological research to facilitate prompt detection and 
communication of emerging safety issues between countries. The data sources used are listed in table 1. 
All datasets held patient level dispensing data which included: a patient identifier, patient 
demographics, date of medicine supply, medicine dispensed, quantity and strength. Medicines were 
mapped from individual country specific codes to the WHO Anatomical Therapeutic Chemical (ATC) 
classification codes.11  
Study design 
We used sequence symmetry analysis,12 which has been validated as an adverse event signal detection 
tool,13 14 to assess the association between proton pump inhibitor use and Clostridium difficile, using 
oral vancomycin as the marker medicine for Clostridium difficile. Oral vancomycin use would be 
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expected to rise after PPI initiation if there is an association with Clostridium difficile infection as oral 
vancomycin is only indicated for Clostridium difficile infections and staphylococcal enterocolitis.15 Oral 
vancomycin has been used as a marker of Clostridium difficile infections in previous research.16 
Vancomycin’s poor absorption from the gastrointestinal tract makes it unsuitable for other types of 
infection so risk of misclassification bias is low.    
A distributive network model 17 was employed. The co-ordinating centre for this study, the University of 
South Australia, developed the statistical analysis code as a stand-alone SAS program for execution by 
each participant in their home institution. The SAS program used global macro variables. Participants 
executed the SAS code and a standardised file of summary results was returned to the co-ordinating 
centre for collation. These standardised files included graphics of the number of people dispensed the 
study medicines each month (prevalent population), the number of people starting study medicines 
each month (incident population), and the results of the sequence symmetry analyses (SSA) results 
including the graphics showing temporal sequences.  
The primary outcome was the first dispensing of oral vancomycin (ATC code C03CA01) as an indicator 
medicine for Clostridium difficile.  Oral vancomycin was only used in Taiwan at the beginning of the 
study period, with injectable formulations of vancomycin used orally at both the beginning of the study 
and in subsequent years.  Hong Kong used injectable forms of vancomycin orally throughout the study 
period, thus, Hong Kong data were not included in the results.  Proton pump inhibitors assessed 
included omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.  Proton pump 
inhibitors dispensed as part of a helicobacter eradication therapy co-pack were excluded.  
In the SSA method, the date of incident dispensing of proton pump inhibitors and oral vancomycin was 
determined for each individual patient. All incident dispensings that occurred within one year of each 
other for the same person were included in the analysis. We excluded patients who initiated any of the 
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study medicines in the first year of data coverage in any dataset to ensure we limited the analyses to 
incident users. The SSA method uses a within person design, making it robust towards confounders that 
are stable over time,12 however, it is sensitive to prescribing trends over time and adjustment was made 
for temporal trends using thee null-effect sequence ratio as described by Tsiropolous.18 Bootstrapped 
95% confidence intervals (CI) were obtained using 500 replicates.  The SSA analyses were restricted to 
sequences of incident dispensings within 12 months of each other to limit the effect of age and other 
potential time-varying covariates on the probability of exposure and outcome. Moreover, a 12-month 
period has better specificity and positive predictive value compared with shorter periods.13 Pooled 
estimates were obtained with a random effects model, using the generic inverse variance method.19. 
Results: 
In  total, 54,957 patients who received oral vancomycin and proton pump inhibitors were included in the 
study. Positive associations were see in all countries apart from Taiwan, where due to low use of oral 
vancomycin, insufficient numbers were available to determine effect. (Table 2) The pooled estimate 
showed a 2.4 fold increased risk (figure 1).  When limited to the Asian countries (Japan, Korea and 
Taiwan) the pooled estimate was 3.16 (95%CI 1.95, 5.10). The temporal relationship was apparent in all 
countries, with effects being observed within the first two weeks of treatment (See figure 2 shows 
results for Australia (national) and Japan Medical Data Centre (JMDC)).  Results for the individual PPIs 
are presented in table 3 for Australia (national) and Korea, the only countries with sufficient numbers to 
undertake individual agent analysis, and show similar risk for each agent.  
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Discussion 
This multi-country study found an elevated risk of Clostridium difficile infections after initiation of 
proton pump inhibitors. Our pooled estimate of 2.4 (95% CI 1.88-3.05) is slightly higher but consistent 
with prior research, with meta-analysis evidence finding an increased odds of 1.65 (95% CI 1.47-1.85). 1  
All countries in the Asia Pacific region had risk estimates greater than 2.0.  When our pooled analysis 
was limited to Asian countries we found a three-fold increased risk which is also consistent with 
previous meta-analysis results from Asian countries OR 3.26, (95%CI 1.91 -5.58.).1  Analysis by individual 
agents showed the risk was present and of similar magnitude for each proton pump inhibitor. 
We observed the highest risk in the Japanese data sets, with risk estimates increased three and five fold 
respectively in the two Japanese data sets, for which confidence intervals overlapped.  These results are 
higher risk estimates than have been reported previously in Japan.  The largest previous Japanese study, 
which was a multi-institution study involving 1025 cases and 878 controls that assessed hospital 
acquired CDI, did not find proton pump inhibitors were a risk factor for CDI, however, assessment of PPI 
use was limited to that prescribed during the hospital stay.20 By comparison our results include 
outpatient proton pump inhibitor use up to one year prior to CDI infection. A small Japanese study, 
limited to 26 cases and 52 controls, assessed risk factors for community acquired CDI, finding no 
association with proton pump inhibitor use.21  Another small study of risk of recurrent infection, 
involving 14 patients with recurrent infection and 62 without also did not find a significant effect of 
proton pump inhibitors on recurrence.22  These latter two studies may have had insufficient sample size 
to demonstrate effect. Finally, a Japanese study amongst a cohort of people who had been prescribed 
injectable antibiotics did find proton pump inhibitors were associated with increased risk of subsequent 
Clostridium difficile infections.23   Previous research in Korea has assessed the relationship between 
recurrent Clostridium difficile infections and PPIs, demonstrating an association.24, 25 No prior studies 
from Korea examined the effect on incident infection.  One small study involving 84 persons from 
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Taiwan found proton pump inhibitors were an independent risk factor for development of Clostridium 
difficile infections (OR 3.2, p=0.014)26, while a second study found of those with Clostridium difficile 
colonization, use of proton pump inhibitors was more common in those who subsequently developed 
infection.27 
While it has been postulated that the acid suppressions mechanism of PPIs may play a role by allowing 
clostridium difficile spores to survive the gastric environment, this may not be the mechanism as 
clostridium difficile spores can survive acid gastric contents.28  Acid levels, though, may affect toxin 
expression. As we previously noted, one in-vitro study found that expression of toxin genes and their 
regulators were different in the presence of PPIs in some clostridium difficile ribotypes.9 Another in vitro 
study also examining the effect of PPIs on expression of colonocyte genes found PPIs decreased their 
expression.29 The consequence of decreased expression includes loss of maintenance of cell junction, 
and reduced production of proteins known to protect the intestinal epithelium, one of which is known 
to protect against clostridium difficile induced intestinal damage. An effect on bile acid metabolism and 
transport was also observed.29  All of these effects have the potential to increase susceptibility to or 
worsen clostridium difficile infection. 
Given one of the possible mechanisms by which PPIs may exert their influence on Clostridium difficile 
infection is toxin expression and that toxin expression differs by ribotype,9 our results, highlight the 
importance of obtaining risk estimates, where possible, from local data as data from other countries 
may not be directly applicable. Our results show slightly higher risk estimates in the Asian countries, 
however, we did not have access to clinical records and so could not ascertain any information on 
whether this could be related to the strain of Clostridium difficile being treated. 
Strengths of our research include the access to national data sets for Australia, Canada, Korea, and 
Taiwan. Our research used a common method and a common analytic approach which ensures results 
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are comparative with regards to method and data variables used.  Limitations of our study include lack 
of diagnostic information at the outpatient level in the majority of countries, and hence the reliance on 
oral vancomycin as the proxy indicator for Clostridium difficile. Oral vancomycin, however, has been 
used as a marker of Clostridium difficile infection in previous research16 and is the sole reimbursed 
indication for oral vancomycin in Australia30,  Canada and Korea31. In Japan it is indicated for “infectious 
enteritis (including pseudomembranous colitis)” caused by vancomycin-sensitive MRSA colitis and C. diff, 
and 2) “sterilization of gastrointestinal tract at bone-marrow transplantation” the other countries it may be 
used for either Clostridium difficile or staphylococcal enterocolitis. A limitation of the method was the 
inability to include results from Hong Kong and Taiwan where the injectable formulation of vancomycin 
is provided orally as a treatment for Clostridium difficile infections, as these dispensings could not be 
distinguished from vancomycin given in the injectable form for other reasons.  A further limitation is 
that oral vancomycin is second line therapy in many countries, with metronidazole being first line 
therapy for Clostridium difficile infections; including in Australia, Japan and Canada.  We did not use 
metronidazole as our indicator of Clostridium difficile infections, however, because metronidazole is 
also indicated for other conditions and thus may have biased the results.  This limitation means that we 
did not include cases of Clostridium difficile treated only by metronidazole only and so will not have 
captured all events.  Finally, we cannot exclude the possibility that some of the differences observed 
across countries may be due to differences in health care practice.  
In conclusion, our results provide further evidence of the association between proton pump inhibitors 
and risk of Clostridium difficile infections.  When analysis was limited to the Asian countries, pooled risk 
estimates were higher than those which had been observed in European and North American 
populations. Further research to confirm reasons underpinning any risk difference in the Asian region is 
required.   
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Table 1: Data sources for the study 
Data source Data type Population 
covered 
Years of 
coverage 
Comments 
Australian Government 
Department of Human 
Services 
National 
pharmacy claims 
data  
23 million 
persons 
2003-2013 Excludes inpatient 
use in public 
hospitals 
Australian Government 
Department of Veterans’ 
Affairs 
Pharmacy claims 
data for 
Australian 
veterans and 
their dependents 
300,000 2001-2012 Excludes inpatient 
use in public 
hospitals. 
Predominantly 
older population 
(median age 80 
years) 
Canadian Institute for 
Health Information 
(CIHI)’s National 
Prescription Drug 
Utilization Information 
System (NPDUIS) 
Database 
National 
Pharmacy Claims 
from public drug 
programs 
 
3.5 million 2001-2012 Data from 7 
Canadian 
provinces 
included in this 
study.  
Includes 
population aged 
65 years and over 
who are eligible 
for coverage by 
provincial public 
drug programs. 
Includes only 
drugs dispensed 
in a community-
based setting.   
Hong Kong Clinical Data 
Analysis and Reporting 
System 
National 
electronic 
healthcare record 
of public hospitals 
and their 
ambulatory 
clinics.  
7 million 2008-2012 Oral vancomycin 
not reimbursed. 
Injectable 
formulation given 
orally. 
Japan Medical Data 
Center database 
Private health 
insurance data 
set for workers 
1,000,000 2008-2013  
Japan Hamamatsu 
Medical University 
Database 
Hospital data set 200,000 1996-2014  
Korea Health Insurance 
Review and Assessment 
National Health 
Insurance data 
50 million 2009-2013  
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Service database (HIRA 
DB) 
set 
Taiwan National Health 
Insurance Research 
Database  
National Health 
insurance data 
set  
23 million 2001-2012 3 million person 
random sample 
data set utilised. 
Oral vancomycin 
not used after 
2005. Injectable 
formulation given 
orally across 
whole time frame.  
 
Table 2:  Sequence symmetry results for association between incident proton pump inhibitor (class) 
supply  and incident oral vancomycin supply. 
 
Study 
Population 
n 
Oral 
vancomycin 
dispensed 
after  PPI 
n 
Oral 
vancomycin 
dispensed 
before PPI 
n 
Crude 
Sequence 
Ratio 
Null Effect 
Sequence 
ratio 
Adjusted sequence 
ratio (95% 
confidence 
intervals) 
Korea 53820 37113 16707 2.22 1.03 2.15 (2.11-2.19) 
Australia 351 257 94 2.734 1.10 2.48 (1.90-3.12) 
Australia 
DVA 
77 49 28 1.75 0.99 1.76 (0.97-2.71) 
Japan 
Hamamatsu 
171 128 43 2.98 0.93 3.21 (2.12-4.55)  
Japan 
Medical Data 
Center 
139 116 23 5.04 0.93 5.40 (2.73-8.75) 
Canada 388 270 118 2.29 1.58 1.45 (1.16-1.79)  
Taiwan# 11 8 3 2.67 0.99 2.70 (-1.60-8.91) 
# Low numbers for Taiwan as a result of preferential use of injectable vancomycin 
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Table 3: Sequence symmetry results for association between incident proton pump inhibitor 
(individual agent) supply and incident oral vancomycin supply. 
 
Study 
Population 
Number of 
people with 
oral 
vancomycin 
dispensed 
after  PPI  
Number  of 
people with 
oral 
vancomycin 
dispensed 
before PPI 
Adjusted sequence 
ratio (95%confidence 
intervals) 
Omeprazole 
Australia 113 82 31 2.41 (1.45, 3.58) 
Korea 14878 9512 5366 1.67 (1.61, 1.72) 
Pantoprazole 
Australia 299 209 90 2.08 (1.57, 2.65) 
Korea 32070 20219 11851 1.71 (1.67, 1.75) 
Lansoprazole 
Australia 18 16 2 7.66 (-1.06 18.99) 
Korea 25917 15731 10186 1.53 (1.50,1.57) 
Rabeprazole 
Australia 104 70 34 1.84 (1.10, 2.69) 
Korea 23021 15474 7547 2.07 (2.02, 2.13) 
Esomeprazole 
Australia 284 192 92 1.90 (1.44, 2.41) 
Korea 20261 12000 8261 1.67 (1.62, 1.71) 
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Figure 1: Pooled estimate for association between incident proton pump inhibitor supply and incident 
oral vancomycin supply. 
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Figure 2:  Temporal relationship of incident PPI supply and incident vancomycin use 
 
 
0
2
4
6
8
10
12
14
16
18
-52 -47 -42 -37 -32 -27 -22 -17 -12 -7 -2 3 8 13 18 23 28 33 38 43 48
N
um
be
r o
f p
er
so
ns
 re
ce
iv
in
g 
or
al
 v
an
co
m
yc
in
Weeks before and after PPI initiation
Australia: national data
Non-causal
Causal
0
2
4
6
8
10
12
14
16
18
-4
9
-4
5
-4
1
-3
7
-3
3
-2
9
-2
5
-2
1
-1
7
-1
3 -9 -5 -1 3 7 11 15 19 23 27 31 35 39 43 47 51
N
um
be
r o
f p
er
so
ns
 re
ce
iv
in
g 
or
al
 v
an
co
m
yc
in
Weels before and after PPI initiation
Japan Medical Data Center
Non-causal
Causal
